Author: OurCrowd

Newsletter: Formula One 3D printing + Stroke therapy

Startup of the Week: Nexa3D enters Formula 1 BrainQ trial offers new hope for stroke victims Hasanat Dewan joins OurCrowd as Chief Innovation Officer Customers flock to ByondXR’s pop-up stores for Lancôme H2Pro: Gates-backed startup joins race to make green hydrogen TytoCare adds $50 million D-ID: From MyHeritage to rich content advertising and film Pop-up antennas slash price of satellite communications Online pharmacy Ro vaccinates seniors at home HIL-CERN collaboration to develop proton therapy for cancer Introductions 1,000 high-tech jobs Startup of the Week:Formula 1 selects Nexa3D’s high-speed 3D printing Williams Racing, the 16-time Formula 1 champion, has selected Nexa3D’s NXE400 ultrafast photoplastic 3D printer to create components for wind tunnels used to test cars and components, reducing manufacturing time from hours to minutes, TCT Magazine reports. “The NXE400 breaks printing speed barriers with its 20X productivity,” Williams said in a statement. “Formula One is a challenging environment that demands a continuous improvement philosophy in order to remain competitive. Our partnership will enable the team to continue to push boundaries in 3D printing, and present new opportunities for Nexa3D...

Read More

[OurCrowd CIO Dr. Hasanat Dewan in Zawya] Microsoft cloud to generate $27bln revenues, 69K new jobs in UAE by 2024

Microsoft’s cloud ecosystem will generate $27 billion in new revenues by 2024 in the UAE, according to a research by the International Data Corporation (IDC). This ecosystem is expected to propel the UAE economy upwards from the 2020 level, creating jobs and driving investment in local economies, including in sustainable solutions which will see a reduction in atmospheric carbon. Read...

Read More

[BrainQ in PR Newswire] BrainQ announces encouraging study results for new therapy to reduce disability after stroke

JERUSALEM, March 11, 2021 /PRNewswire/ — BrainQ, the Israeli start-up with an AI-powered therapeutic platform, today revealed the encouraging results of their Randomized Controlled Trial (RCT) which supported a recently granted request for FDA Breakthrough Device Designation. The pilot trial data will be presented as part of the International Stroke Conference between March 17-19. Read more...

Read More